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Abstract Nitric oxide (NO), a potent vasodilator critical in
maintaining vascular homeostasis, can reduce blood pressure
in vivo. Loss of constitutive NO generation, for example as a
result of endothelial dysfunction, occurs in many pathological
conditions, including hypertension, and contributes to disease
pathology. Attempts to therapeutically deliver NO via organic
nitrates (e.g. glyceryl trinitrate, GTN) to reduce blood pressure
in hypertensives have been largely unsuccessful. However, in
recent years inorganic (or ‘dietary’) nitrate has been identified
as a potential solution for NO delivery through its sequential
chemical reduction via the enterosalivary circuit. With dietary
nitrate found in abundance in vegetables this review discusses
epidemiological, pre-clinical and clinical data supporting the
idea that dietary nitrate could represent a cheap and effective
dietary intervention capable of reducing blood pressure and
thereby improving cardiovascular health.
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Introduction
The Burden of Hypertension
Cardiovascular disease is a significant disease burden world-
wide, responsible for approximately 17.5 million (31 %)
deaths each year according to the World Health Organization
(WHO) [1]. Hypertension particularly has been estimated to
account for nearly 10 million of these deaths, and is now
considered the leading risk factor for global disease burden
[2]. The annual economic impact of hypertension in the US
alone (through both direct and indirect costs) has been esti-
mated to be $46.4 billion, and by 2030 is predicted to rise to
nearer $274 billion [3]. Recent evidence, from both primary
and secondary care electronic health records in the UK, sup-
ports the view of blood pressure as a continuum with increas-
ing risk of cardiovascular disease with increasing pressures
[4]. In particular this study suggested that perhaps current
guidelines for target blood pressures are set too modestly.
The study demonstrated that those with hypertension (i.e.
blood pressures of ≥140/90mmHg) at the age of 30 developed
cardiovascular disease 5 years earlier than normotensive coun-
terparts. In addition they demonstrated that, as expected, for
many cardiovascular diseases a linear association with blood
pressure is evident. However, perhaps unexpectedly, it was
identified that in individuals with systolic blood pressures of
90–114 mmHg compared to 115–129 mmHg, disease risk
continued to be substantially lower. Importantly, the
SPRINT [5] (NCT 01206062) study in the US, looking at
more aggressive blood pressure lowering in the over 50s to
systolic pressures of 120 mmHg, has demonstrated reduced
rates of cardiovascular events as compared to lowering of
systolic pressures to 140 mmHg (current target blood pressure
according to guidelines) including ∼1/3 reduced risk of heart
attack, heart failure and stroke and reduced risk of death by
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∼1/4. Such observations provide support for early and inten-
sive blood pressure intervention and highlight a rationale for
further active blood pressure lowering approaches to be
adopted even by those classified according to current norms
as having ‘healthy’ blood pressure.
Roughly 80 million (1 in 3) adults in the US are hyperten-
sive, and in 2011 only 54 % of these individuals were estimat-
ed to have the condition under control [3]. In total, 83 % were
aware of their hypertension, but only 77%were being actively
treated. As both hypertension (≥140/90 mmHg) and even se-
vere hypertension (≥180/110 mmHg) are often asymptomatic
[6] it is not entirely surprising that the remaining 17 % had no
knowledge of their condition [3], a pattern also observed in
Canada and England [7].
Thus, taking all of the above into account there is a contin-
ued imperative to find new interventions that are not only
acceptable for the relatively ‘well’ population but also inter-
ventions for those where poly-pharmacy is not the preferred
approach.
A Drive for Dietary Intervention in Primary Prevention
and Treatment of Rising Blood Pressure
First line treatment for patients with raised blood pressures,
but not at levels appropriate for pharmacotherapy, is lifestyle
modification. However, such an approach becomes perhaps
more important when one considers the substantial benefits
accrued, in terms of cardiovascular disease-free years of life,
when reducing blood pressure well below conventional ac-
cepted levels of ‘good’ blood pressure i.e. 90–114 mmHg of
systolic pressure versus 115–129 mmHg [4]. Interventions
that are not drug-based are perceived as beingmore acceptable
for patients, particularly those that are ‘symptomless’.
Furthermore, with the burden of uncontrolled, untreated and
undiagnosed hypertension rising in low and middle income
countries [1, 8], effective interventions offering a cheap and
universally acceptable treatment, resulting in improved car-
diovascular health worldwide, are desirable.
Numerous studies have demonstrated the benefits of indi-
vidual lifestyle measures upon blood pressure including, and
of particular relevance to this review, diet. For some dietary
constituents our understanding of the impact and mechanisms
of action of these interventions is advanced, whilst in contrast
the impact of others is more controversial. As an example salt
reduction has been widely investigated with numerous and
large-scale clinical trials demonstrating efficacy in blood pres-
sure reduction [9]. These studies have resulted in policy
change in numerous countries attempting to reduce salt intake
and thus hypertension and cardiovascular disease burden
worldwide. Another dietary intervention thought to influence
blood pressure [10], that has also resulted in significant policy
change is that of fruit and vegetable intake (NHS, 5 a day; US,
7 a day). However, unlike salt reduction, increasing fruit and
vegetable intake has not been so easy. This is despite the fact
that large-scale meta-analyses very convincingly demonstrate
a decreased cardiovascular disease incidence with increased
intake, with five portions of fruit and vegetables per day being
the optimum level of intake [11]. In addition to the socioeco-
nomic reasons that might underlie this [12] there is also the
possibility that the considerable uncertainty and controversy
with respect to mechanism of action and identification of the
key element responsible for the benefits plays a role. Recently,
however, there has been growing support for the view that the
naturally occurring compound inorganic (or ‘dietary’) nitrate
(NO3
−) may play a role and it is this constituent of vegetables
that is the focus of this review.
Inorganic nitrate is a key nutritional constituent of many
vegetables, including spinach, beetroot and celery [13, 14].
All vegetables take up nitrate from the soil since it is critical
in providing a supply of nitrogen. Importantly, those vegeta-
bles that possess large green leaves tend to extract more ni-
trates from the soil due to the need for growth and accordingly
green leafy vegetables contain the highest levels of nitrate
found in the diet [15]. This fact is of interest when one con-
siders that of all the fruits and vegetables that confer protection
over the cardiovascular system it is the green leafy vegetables
that provide the greatest benefit [16]. This review will discuss
some of the epidemiological evidence for significant blood
pressure reduction by dietary nitrate, some of the pre-clinical
evidence in animal models and prospective clinical trials test-
ing efficacy of dietary nitrate as an intervention.
NO Supplementation and Cardiovascular Health
The importance of the L-arginine/NO pathway in cardiovas-
cular health has long been established, with endogenous NO
production by endothelial NO synthase (eNOS) found to play
a pivotal role in regulating vascular tone and blood pressure in
both pre-clinical and clinical studies [17, 18]. With NO pro-
duction critical in helping maintain healthy vascular homeo-
stasis [19] and reduced endogenous NO production involved
in the pathogenesis of hypertensive disorders [20] it makes
sense to investigate NO supplementation as a treatment for
hypertension.
In the late nineteenth century, organic sources of NO such
as nitroglycerin (GTN) were used to restore NO to the vascu-
lature. However, with rapid NO release from these com-
pounds, vasodilatory effects were acute and had no long-
term ability to reduce blood pressure. The latter being due in
part to the tachyphylaxis that develops rapidly in response to
organic nitrates [21, 22] and also, discovered much later, due
to the fact that many of these compounds induce endothelial
dysfunction per se [23]. Such characteristics have of course
substantially limited the clinical utility of this class of com-
pounds, and although the organic nitrates are still used for
acute symptomatic relief in angina patients and in the acute
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heart failure scenario, the long-term use for blood pressure
reduction is not considered a viable first-line option. There is
some evidence, however, that in patients with systolic hyper-
tension once daily low-dose regimens may be useful [24, 25].
This beneficial effect is likely due to the organic nitrate-
induced improvements in arterial stiffness rather than periph-
eral vasodilation [26].
The Potential of Inorganic Nitrate—the Enterosalivary
Circuit
Until recently, endogenous inorganic nitrite (NO2
−) and nitrate
(NO3
−) were considered primarily as oxidized, largely inac-
tive, waste metabolites of NO. However, we now know that
both anions can act as storage forms of NO (for reviews see
Lundberg et al. [27] and Rathod et al. [28]) and under certain
conditions are being reduced back to bioactive NO.
For plasma nitrate to be successfully converted to NO (re-
gardless of whether the source of nitrate is from NO oxidation
or through ingestion of nitrate-rich foods), we rely heavily on
the ‘enterosalivary circuit’. The oral bioavailability of ingested
nitrate is near 100 % [29], as nitrate can be absorbed readily
across the gut wall (by as of yet unknown mechanisms) and
transported in the blood plasma. It is estimated that 60–75 %
of this nitrate is lost from the plasma by excretion within 48 h
[30]. However, approximately 25 % of nitrate in the circula-
tion becomes concentrated in the salivary glands through ac-
tive uptake from the circulation by the sialin transporter [31].
As a result, nitrate is released into the oral cavity generating up
to 10 times higher saliva concentrations than that in the plasma
[32, 33]. It is within the oral cavity that nitrate comes into
contact with facultative bacteria [34] which reduce nitrate to
nitrite, that is then swallowed and absorbed across the gut
wall, resulting in increased plasma nitrite levels [32, 35]. It
is now widely accepted that disruption of the enterosalivary
circuit either through antibiotic administration [36] or through
collection of all saliva prior to swallowing [32, 35, 37•] pre-
vents increases in plasma nitrite ordinarily seen following oral
inorganic nitrate supplementation.
Critical for biological activity of nitrate are endogenous
nitrite reductases in the circulation [38], such as XOR [39,
40], which reduce plasma nitrite further to bioactive NO.
This NO is then free to exert its beneficial effects on the car-
diovascular system e.g. inducing vasodilation, improving
measures of arterial stiffness and thus reducing blood pres-
sure. A great many of the beneficial effects of NO are medi-
ated by cyclic guanosine monophosphate (cGMP) (for a re-
cent review see Francis et al. [41]) and following inorganic
nitrate supplementation, increases in this sensitive marker of
NO bioactivity [42] are observed [43–45]. The hypotensive
effects of dietary nitrate through this pathway have now been
investigated with success in human and animal studies,
findings, which to some extent, have been supported by some
epidemiological data.
Epidemiological Evidence
Fruit and Vegetable Intake, Blood Pressure
and Cardiovascular Disease Risk
Whilst there is no conclusive epidemiological evidence to date
supporting dietary nitrate intake reducing blood pressure, a
number of studies have shown that increased consumption
of fruits and vegetables reduces systolic and diastolic blood
pressure by between 3–6 and 1–3mmHg, respectively [10, 46,
47]. This reduction is thought to underlie a substantial propor-
tion of the reductions in both cardiovascular disease risk and
mortality associated with fruit and vegetable consumption
[48–50].
The beneficial effects of such a diet have been proposed to
be due to a number of components, including macronutrient
composition e.g. protein, fat and carbohydrate [51], antioxi-
dants [52], fiber [53] and potassium [54, 55]. However, such
propositions do not fully or sufficiently account for the chang-
es in blood pressure observed on a fruit and vegetable-rich diet
[56], and meta-analyses have even concluded there appears to
be no significant benefit from supplementation with antioxi-
dants or potassium [57, 58]. Recently however, it has been
proposed that inorganic nitrate may underlie at least part of
the beneficial cardiovascular effect of such a diet.
This latter proposal is of particular interest since studies
have shown that the greatest protection provided by fruit and
vegetables is derived from the ‘green leafy’ vegetables [16,
59]. Typically, these groups of vegetables contain the highest
levels of nitrate [14, 15]. However, conclusive evidence
linking the inorganic nitrate content of vegetables with reduc-
tions in cardiovascular disease risk remains elusive due to a
number of significant hurdles. These hurdles have recently
been debated in an NIH workshop entitled ‘Dietary Nitrate
and the Epidemiology of Hypertension and Cardiovascular
Disease’ that was held in Washington in September 2014
(http://www.nhlbi.nih.gov/research/reports/2014-dietary-
nitrate). One particularly prominent issue highlighted in this
workshop is that accurate and reliable estimates of dietary
nitrate ingestion are lacking. Importantly, the nitrate content
of vegetables is highly variable, being dependent on a number
of different factors, not least the nitrate content of the soil
where the vegetables are grown, the presence or not of
nitrogen-based fertilizers and the time of the day/year of har-
vesting. A key recommendation made by the workshop at-
tendees is that contemporaneous assessment of nitrate/nitrite
content of the diet, with assessment of blood pressure, in large
cohort and population studies should be conducted together
with analysis of actual exposure through measurement of in
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vivo nitrate/nitrite levels in plasma, urine or saliva. Such a
study would be critical in confidently assessing the possible
association of nitrate ingestion with cardiovascular disease
risk.
The Effects of a Traditional Japanese Diet on Blood
Pressure
There are a number of observations that support the proposals
made by The NIH Workshop attendees. The traditional
Japanese diet, which is typically high in inorganic nitrate from
vegetables such as ta cai, Chinese cabbage and spinach [60],
has been associated with lower systolic and diastolic blood
pressures. On the contrary, a westernized diet in the same
Japanese population was associated with higher blood pres-
sure [61]. The effects of a traditional Japanese diet (delivering
18.8 mg/kg/day) compared to a control diet (∼equal to the
ADI of 3.7 mg/kg/day) have been investigated in a clinical
study expanding on this finding. The traditional Japanese diet
resulted in an average decrease in mean diastolic blood pres-
sure of 4.5 mmHg (P=0.01), but had no significant effect on
systolic blood pressure [60].
Importantly, in this study they demonstrated that the tradi-
tional Japanese diet significantly increased plasma and sali-
vary nitrate compared to a control diet, from 43 to 154 μM
(P< 0.001) and 200 to 570 μM (P< 0.001), respectively.
Crucially, plasma nitrite was also increased from 132 to
204 nM (P<0.01) [60], suggesting commensal bacteria suc-
cessfully converted nitrate to nitrite via the enterosalivary cir-
cuit. Such observations perhaps provide clues to the apparent
longevity and reduced cardiovascular risk in those maintain-
ing a traditional Japanese diet [62, 63].
Pre-clinical Experimental Evidence
Fortunately, in pre-clinical animal studies it has been demon-
strated that the enterosalivary circuit of nitrate is intact. For
example, in both rats and mice, supplemental feeding with
inorganic nitrate increases plasma nitrite levels resulting in
NO-mediated bioactivity [43, 64–66]. In addition to this, lim-
iting intake of nitrate and nitrite results in rapid depletion of
tissue nitrite levels and reductions in cGMP signaling path-
ways, suggesting reduced NO bioactivity [67]. Finally inter-
ference with the oral nitrate-reducing bacteria eliminates ni-
trate bioactivity [66].
This similarity with humans has therefore permitted inves-
tigation into the effects of nitrite and nitrate on blood pressure
in animal models of hypertension including Wistar Kyoto
(WKY) rats (both with and without phenylephrine induced
hypertension), spontaneously hypertensive rats (SHR), ‘two-
kidney 1-clip’ rats and rats subjected to unilateral nephrecto-
my and a chronic high-salt diet [65, 68–72]. In these models
nitrate reduced mean arterial blood pressure by between ∼20
and 60 mmHg. It has also been shown that the blood pressure
lowering effect of nitrate in the SHR and WKY models is
XOR-dependent and can be blocked by concomitant dosing
with XOR inhibitor allopurinol [70].
In addition to this, nitrate has been found to ameliorate
pulmonary arterial hypertension (PAH) in mice subjected to
hypoxia for 3 weeks. Not only does it significantly reduce
right ventricular pressure, but also reduced left ventricular
hypertrophy and vascular remodeling [43]. These effects were
associated with increases in plasma and lung nitrite and
cGMP, with the beneficial effects of nitrate being greatly re-
duced following co-dosing with allopurinol. Interestingly, the
effects were also reduced in eNOS knockout mice, suggesting
that in addition to XOR, eNOS may also be functioning as a
nitrite reductase within the pulmonary vasculature.
Some concern has been raised with respect to the relevance
of some laboratory data regarding nitrate supplementation in
mice (3 mmol/kg/day) to the human scenario [73]. However,
whilst a dose of 3 mmol/kg/day in rodents produces rises in
circulating nitrite that are bioactive, if extrapolated to humans
(∼210mmol/day for a 70-kg individual) such doses are simply
not required to get a proportional rise in plasma nitrite in
humans. A single dose of 5.5 mmol in the form of beetroot
juice was sufficient to see a 1.6-fold rise in plasma nitrite in
humans and a 10-fold increase in plasma nitrate. In a separate
study assessing the activity of potassium nitrate capsules cir-
culating levels of nitrite were raised 1.3- and 2-fold in re-
sponse to 4 and 12 mmol nitrate, respectively [44]. The exact
reason for this difference between mice and humans is pres-
ently unknown, but may be due to inter-species differences in
the enterosalivary circuit, for example with potential differ-
ences in bacterial nitrate reductase activity, nitrate excretion
and nitrite absorption across the gut lining. It is noteworthy
however, that rats may be different to mice. It has been shown
that doses of nitrate that resemble those consumed by humans
in a nitrate and vegetable-rich meal do effectively lower blood
pressure in rats [64, 66], highlighting again clear species dif-




The activity of the enterosalivary circuit in humans was first
described in a clinical trial by Lundberg and Govoni when
they showed that plasma nitrite significantly increases follow-
ing an oral sodium nitrate load or in response to a 300-g
portion of spinach [32]. This phenomenon has since been
observed in a great number of studies, with participants given
oral nitrate supplementation in a range of ways, including
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vegetables, juice, modified breads and potassium/sodium ni-
trate capsules (see Tables 1 and 2).
Whilst the earliest observation of nitrate supplementation
lowering blood pressure dates back to 1927 [93], it is the more
recent observations that have raised the intense interest cur-
rently in the possible use of dietary nitrate as an anti-hyper-
tensive. This interest was initiated in 2006 when Larsen et al.
first demonstrated that a single oral sodium nitrate load of
0.1 mmol/kg/day for 3 days reduces diastolic blood pressure
by 3.7 mmHg (P=0.002). Soon after this, in 2008,Webb et al.
demonstrated that a single dose of 22.5mmol nitrate, provided
in 500 ml beetroot juice, was capable of acutely decreasing
systolic and diastolic blood pressure by 10.4 mmHg (P<0.01)
and 8.1 mmHg (P<0.01), respectively: an effect still evident
24 h after ingestion with blood pressure remaining ∼6 mmHg
lower than at baseline. Since then, numerous studies have
been undertaken, investigating acute and chronic effects on
blood pressure (see Table 1) as well as demonstrating dose-
dependency of these effects [44] and successfully using a va-
riety of sources of nitrate supplementation. Importantly dose-
ranging studies have suggested that in healthy volunteers,
somewhere between 4–12 mmol of nitrate lies a threshold
dose for blood pressure lowering in individuals with ‘healthy’
blood pressures [44], although some studies have demonstrat-
ed efficacy with lower doses (see Table 1).
Table 1 summarizes key information from clinical trials
reporting effects of dietary nitrate supplementation on blood
pressure of healthy volunteers. Although results from these
studies vary in the degree of blood pressure improvement, as
well as showing reductions in systolic blood pressure, diastol-
ic blood pressure, or both, the general conclusion, as drawn by
a recent meta-analysis by Siervo et al., is that dietary nitrate
supplementation is associated with a significant reduction in
systolic blood pressure (P<0.001) [94•]. In the latter analysis,
meta-regression found an association between daily inorganic
nitrate intake and change in systolic blood pressure (P<0.05).
Whilst some studies have reported a significant decrease in
diastolic blood pressure, in this meta-analysis the overall ef-
fect of nitrate on diastolic blood pressure was not significant.
Patient Studies
Although reports of blood pressure reductions in healthy vol-
unteers have been encouraging and highlight the potential of
inorganic nitrate for reducing blood pressure and cardiovascu-
lar disease risk, it was only in 2013 when the effects of nitrate
on blood pressure in higher risk patient populations began to
be reported. In 2013, Ghosh et al. reported a significant reduc-
tion in blood pressure in drug naïve hypertensive patients
(with average baseline blood pressures of 152/90 mmHg),
with impressive and significant reductions in both systolic
and diastolic blood pressure (11.2 mmHg (P<0.001) and
9.6 mmHg (P<0.001), respectively) following an acute dose
of 3.3 mmol nitrate administered in beetroot juice. Two years
later, results from a larger 4-week, randomized double-blind,
placebo-controlled trial, published by same group, reported
significant and sustained reductions in systolic and diastolic
blood pressure measured in the clinic as well as using 24-h
ambulatory blood pressure monitoring (ABPM) and home
blood pressure measurements. Reductions following con-
sumption of 6.4 mmol/day nitrate varied between 7.7–
8.1 mmHg (systolic) and 2.4–5.2 mmHg (diastolic) using
the different methods of measurement, but all reductions were
statistically significant [87•]. In this study patients were strat-
ified into two groups, half were classified as stage 1 and the
other half were stage 2 not to target, meaning that their blood
pressure was raised despite taking one or more anti-
hypertensive medication. On average the stage two patients
were on two medications. Analysis of this group separately
from the stage 1 patients indicated blood pressure lowering
activity in both cohorts with, if anything, greater efficacy in
the stage 2 patients.
Whilst the above results are encouraging, there have also
been reports failing to demonstrate activity in similar cohorts.
Bondonno et al., in a cohort of individuals classified as ‘pre-
hypertensive’, showed no blood pressure lowering with a di-
etary nitrate dose of 400 mg/day which equates to just below
6.5 mmol [88]. In 2015, the same group demonstrated no
significant effect on blood pressure in stage 2 hypertensive
patients using 7 mmol/day nitrate, despite successfully in-
creasing plasma nitrite levels [86•]. The reason for this dis-
crepancy between the studies is uncertain. However, the pa-
tients in the former study had baseline systolic blood pressure
recruitment criteria of 120–139 mmHg range with average
blood pressures at baseline of the cohort of ∼129/76 mmHg.
In the second study blood pressure was well controlled in the
treated hypertensives with baseline blood pressures of ∼128/
74 mmHg. It is possible that the lack of efficacy, in both of
these studies, might relate to the lower baseline blood pres-
sures particularly when one considers that the blood pressure
lowering activity of any single dose of anti-hypertensive in-
creases with increasing baseline blood pressure [95]. It is
worth noting that the blood pressure lowering effect of nitrate
in healthy volunteers with baseline blood pressures, not dis-
similar to these studies, was minimal with a dose of 12 mmol
and absent with a dose of 4 mmol suggesting that perhaps with
higher doses greater efficacy may have been evident.
Another group of patients apparently resistant to the blood
pressure lowering activity of nitrate are type II diabetics.
Gilchrist et al. found no reduction in 24-h ambulatory blood
pressure in patients who received 7.5 mmol/day of nitrate in
beetroot juice for 2 weeks, despite causing a significant rise in
plasma nitrite [90]. It is noteworthy that baseline blood pres-
sures in this cohort were ∼135/70 mmHg ABPM and thus, as
with the studies mentioned above, this lower baseline pressure
may have had an impact upon efficacy. In addition, the
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volunteers received their dose of dietary nitrate (beetroot
juice) in the evening. Studies monitoring ambulatory blood
pressure show blood pressure lowering effects predominantly
occurring during the daytime, following morning ingestion.
This difference between protocols may underlie the disparity
in results. The authors of this paper did also suggest that since
the individuals recruited had a number of comorbidities they
were taking a range of different medications and it is possible
that this might also have had an impact upon efficacy.
Despite this discrepancy, it is encouraging that in other high
risk patient populations, nitrate has been used with success,
lowering systolic blood pressure of older and overweight pa-
tients by 5 and 7 mmHg, respectively after ingesting
∼10 mmol (for 2 days) and ∼5.5 daily (for 3 weeks), respec-
tively [89•, 91•]. Importantly, these patients had baseline
blood pressures of 125/74 and 135/77 mmHg. However, per-
haps a difference from the negative studies mentioned above
is that higher doses of nitrate were administered in one case
whilst in another the study duration was longer. In patients
with peripheral artery disease (PAD), diastolic blood pressure
was also reduced by 8 mmHg at rest and during exercise, after
consuming a single dose of 9.1 mmol nitrate, although systolic
blood pressure was unaffected. Interestingly, 2 min into exer-
cise recovery, systolic blood pressure was 18 mmHg lower in
the nitrate treated group [92•]. This surprising discovery sug-
gests that although at rest systolic blood pressure was not
affected, there appears to be some effect following periods
of physical activity. With reduction of nitrite to NO known
to be promoted in hypoxic conditions [96, 97], it may be that,
in these PAD patients, bouts of ischemia during exercise pro-
mote the reduction of plasma nitrite to NO resulting in the
post-exercise reductions in blood pressure observed.
In sum, the beneficial effects of nitrate supplementation
upon blood pressure are not limited to healthy individuals,
but extend to (and are even enhanced in some) patient popu-
lations (see Table 2 for further information and references).
Important Considerations
Antibacterial Mouthwash and the Enterosalivary Circuit
There are now numerous reports supporting the critical role of
the enterosalivary circuit in the effects of nitrate on blood
pressure. In 2008 Govoni et al. demonstrated that in partici-
pants using an antibacterial mouthwash, to eliminate bacterial
conversion of nitrate to nitrite selectively within the oral cav-
ity, rises in circulating nitrite in response to an oral nitrate load
are prevented [36]. Furthermore, in 2008, Webb et al. demon-
strated in healthy volunteers that if recruits were prevented
from swallowing their saliva for 3 h following an acute dose
of nitrate, then the expected drop in blood pressure was no
longer observed [35]. More recently, Kapil et al. demonstrated
that not only is the enterosalivary circuit critical in blood pres-
sure responses to acute and chronic dosingwith dietary nitrate,
but it is also important in normal physiological blood pressure
control. In the absence of any dietary nitrate intervention,
daily use of an antiseptic mouthwash caused a decrease in
salivary and plasma nitrite levels of healthy volunteers by 90
and 25 %, respectively, an effect associated with an average
increase in blood pressure of 3.5 mmHg [37•]. Evidence sug-
gests that ∼31 % of the UK population regularly uses mouth-
wash [98] and nearer 60 % in the US [99]. The potential
cardiovascular implications of such widespread daily use of
mouthwash is therefore somewhat concerning, particularly in
western society where a multitude of other cardiovascular risk
factors are already highly prevalent. Whilst the use of mouth-
wash is in some cases a necessity, a more balanced view of the
risks and benefits should certainly be considered following
these findings with the aid of larger prospective clinical trials.
Nitrate Sources and Placebos
As mentioned previously, various distinct sources have been
tested in clinical studies investigating the effects of nitrate on
blood pressure, including nitrate capsules and various forms
of food supplementation, from spinach to beetroot juice and
even nitrate enriched bread products (see Tables 1 and 2).
In recent years however, beetroot juice has been particular-
ly popular as a convenient way to deliver a controlled dose of
inorganic nitrate, both using concentrated shots and traditional
beetroot juice drinks. However, it is worth noting that a recent
study by Jajja et al. showed it is important for investigators to
quantitatively assess the concentration of nitrate in their beet-
root juices to confirm levels reported by the commercial sup-
plier. For example, in this paper, the supplier reported a nitrate
dose of 300–400 mg per bottle, but Jajja et al. found a con-
centration of only 165 mg per bottle. Such variations may
underlie some of the differences in outcome reported in the
literature.
Also, initially in trials using beetroot juice, as shown in
Tables 1 and 2, placebo controls consisted of water,
blackcurrant juice, orange juice or rice milk. This is important
to consider when interpreting results from these studies, and
when designing future studies, as blood pressure has been
reported to be significantly influenced by ‘placebo effect’
[100, 101]. Fortunately, recent development in the field of
nitrate research has led to the production of a nitrate-
depleted beetroot juice using an ion exchange system [102].
Using this process means nitrate can be removed from the
juice, but the remaining nutrient/mineral composition, as well
as the taste and appearance, remain largely unchanged [103].
This process means beetroot juice and nitrate-depleted beet-
root juice offer a convenient way to provide dietary nitrate in
double-blind, randomized clinical trials with appropriately
matched treatments and placebos.
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Potential Future Directions and Implications
Heart Failure
It is now quite clear that inorganic nitrate has the potential
to reduce blood pressure in both healthy individuals and
hypertensive patients. One major implication of this is that
such reductions in blood pressure could help reduce prev-
alence of co-morbidities, particularly such as heart failure,
since hypertension is the most common risk factor shared
by patients with heart failure (preceding heart failure in
66–90 % of cases [104, 105]).
However, it is also possible that inorganic nitrate may
be capable of moderating cardiac hypertrophy/heart fail-
ure directly. Constitutive NO has been identified as an
important modulator of cardiac hypertrophy as chronic
inhibition of NO synthase, using L-nitroarginine methyl
ester (L-NAME), has been shown to significantly increase
angiotensin II-induced cardiac fibrosis in rats [106]. Both
nNOS and eNOS knockout mice also develop cardiac
hypertrophy spontaneously, with double knockout mice
expressing a more severe cardiac hypertrophy phenotype
[107, 108]. In accord with these observations is the find-
ing that in patients with heart failure, a genetic variant of
eNOS, resulting in shortened enzyme half life, is associ-
ated with increased mortality [109]. Low-level expression
of NO therefore appears to be protective and loss of con-
stitutive NO generation, for example as a result of endo-
thelial dysfunction, may result in the loss of a braking
mechanism of cardiac hypertrophic pathways. By restor-
ing the ‘lost’ NO through nitrate supplementation such
protective pathways may be restored. In support of this
possibility, using a mouse transaortic constriction model
of heart failure, sodium nitrite has recently proved to
preserve cardiac ejection fraction, limit left ventricle re-
modeling and attenuate brain natriuretic peptide levels
[110].
In healthy individuals inorganic nitrate also improves
mitochondrial efficiency [111] and increase exercise ca-
pacity [112] and likewise nitrate has recently been shown
to improve muscle contractile function and exercise capac-
ity of heart failure patients [113–115]. Such findings sug-
gest that inorganic nitrate supplementation is likely to be
well tolerated and even beneficial in this patient popula-
tion. However, as of yet the direct effects on the heart have
not been established, and the potential for modulation of
heart failure development and progression have not yet
been investigated. Animal models of cardiac hypertrophy
and heart failure are therefore likely to help us understand
whether or not nitrate/nitrite/NO has a direct effect on car-
diovascular remodeling and performance in addition to the
beneficial effects on mitochondrial oxidative function,
which have already been observed.
Dialysis
Another patient population that could also potentially benefit
from dietary nitrate research is dialysis patients. The impor-
tance of nitrate in cardiovascular health and blood pressure
homeostasis has recently helped further understanding regard-
ing the increased risk of cardiovascular-associated death ob-
served in these patients. Little was previously understood
about the mechanism(s) behind this phenomenon, but in
2013 it was found that the dialysis process reduced plasma
nitrite levels by 57 % and nitrate by 84 %, likely resulting in a
decrease in NO production and having negative effects on
cardiovascular homeostasis [116]. Such a finding is likely to
help, at least in part, explain the cardiovascular complications
suffered by dialysis patients and importantly, results from fur-
ther studies assessing the impact of dietary nitrate on cardio-
vascular outcome for dialysis patients would be of value.
Conclusions
In conclusion, inorganic nitrate has proven time and again to
be effective in reducing blood pressure in healthy individuals,
and largely successful in reducing blood pressure in hyperten-
sive patients. Importantly, these effects on blood pressure are
dose-dependent, rely on the intact enterosalivary circuit (and
can therefore be prevented by use of antibacterial mouth-
wash), are not susceptible to tachyphylaxis and are relatively
consistent despite using different nitrate sources (capsule,
beetroot juice, vegetables and bread). Thus, dietary nitrate
offers a potentially cheap and effective way to help reduce
blood pressure in hypertensives. In addition, dietary nitrate
could also potentially offer options to improve cardiovascular
outcome in other patient groups such as dialysis and heart
failure patients, particularly since, in addition to blood pres-
sure lowering, nitrate has been shown to be beneficial in im-
proving exercise performance, tolerance and mitochondrial
function. Although the effects (or perhaps lack of) in certain
hypertensive patient subgroups, such as diabetics, remain to
be further understood, in a large proportion of the general
population, a diet rich in fruit and vegetables, or an alternative
source of nitrate supplementation such as beetroot juice, is
likely to be of significant benefit to cardiovascular health.
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